person · Reporting owner
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Director | July 26, 2021 | July 28, 2021 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | December 02, 2025 | December 05, 2025 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | 10% owner | August 03, 2021 | August 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date July 26, 2021 · Filed July 28, 2021
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Private Growth Equity Fund, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,745,333 |
Last balance in matching sequence
After 2021-07-26 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-07-26 · Conversion · Acquired 4,209,573 · Balance 4,209,573 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 2 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 5,182,833 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 3 · 2021-07-26 · Purchase · Acquired 1,562,500 · Balance 6,745,333 F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 973,260 |
Reported balance
After 2021-07-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 973,260 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-26 · Conversion · Disposed 1,274,431 · Balance 0 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | IndirectSee footnote | 0 |
Reported balance
After 2021-07-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date.
F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports
F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration.
F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports.
STANDARD BIOTOOLS INC.
Report date December 02, 2025 · Filed December 05, 2025
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund II GP, LLC, Casdin Private Growth Equity Fund, L.P., Casdin Eli
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,875,000 |
Reported balance
After 2025-12-02 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-02 · Purchase · Acquired 125,000 · Balance 71,875,000 F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,950,000 |
Reported balance
After 2025-12-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-12-03 · Purchase · Acquired 75,000 · Balance 71,950,000 F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 72,100,000 |
Reported balance
After 2025-12-04 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2025-12-04 · Purchase · Acquired 150,000 · Balance 72,100,000 F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 13,939,637 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 13,939,637 F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 2,744,219 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,744,219 F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 2,901,062 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,901,062 F5: The securities are owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F5: The securities are owned directly by Eli Casdin.
F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Tenaya Therapeutics, Inc.
Report date August 03, 2021 · Filed August 04, 2021
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Private Growth Equity Fund, L.P., Casdin Capital, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,374,849 |
Reported balance
After 2021-08-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-08-03 · Conversion · Acquired 2,374,849 · Balance 2,374,849 F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,224,849 |
Reported balance
After 2021-08-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-08-03 · Purchase · Acquired 850,000 · Balance 3,224,849 F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 361,969 |
Reported balance
After 2021-08-03 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-08-03 · Conversion · Acquired 361,969 · Balance 361,969 F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). |
| Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-03 · Conversion · Disposed 2,012,880 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-03 · Conversion · Disposed 361,969 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-03 · Conversion · Disposed 361,969 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF).
F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any.
F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF).
F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 150,000 | $1.45 | $217,020.00 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 72,100,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 75,000 | $1.44 | $108,037.50 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,950,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 01:59 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 125,000 | $1.42 | $177,512.50 |
DisclosureSEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 7,550,000 | $1.30 | $9,838,405.00 |
DisclosureSEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.30 to $1.3843. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 150,000 | $1.43 | $214,875.00 |
DisclosureSEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,200,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4290 to $1.4396. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 450,000 | $1.30 | $586,260.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,050,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2788 to $1.3500 . The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 350,000 | $1.28 | $448,910.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,600,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2758 to $1.2870. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 275,000 | $1.23 | $339,405.00 |
DisclosureSEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2247 to $1.2421. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 17, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 225,000 | $1.22 | $275,580.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,975,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2175 to $1.2299. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.24 | $309,800.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2364 to $1.2434. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 23:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 450,000 | $1.20 | $541,395.00 |
DisclosureSEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,500,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1978 to $1.2098. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 375,000 | $1.19 | $445,837.50 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 62,050,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1865 to $1.1913. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 300,000 | $1.20 | $358,800.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,675,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1881 to $1.2053. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 275,000 | $1.17 | $321,915.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,375,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1688 to $1.1732. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| November 07, 2025 Filed Nov 13, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 225,000 | $1.12 | $252,765.00 |
DisclosureSEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,100,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1153 to $1.1321. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 100,000 | $1.29 | $128,920.00 |
DisclosureSEC source: 0000919574-25-005636 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2889 to $1.2895. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 23:08 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.28 | $319,350.00 |
DisclosureSEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,775,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2621 to $1.2930. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 23:08 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 250,000 | $1.27 | $316,400.00 |
DisclosureSEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,525,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2414 to $1.2765. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 125,000 | $1.26 | $157,937.50 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,275,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 200,000 | $1.24 | $248,180.00 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,150,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2311 to $1.2475. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 22, 2025 Filed Aug 27, 2025 00:46 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share | 200,000 | $1.26 | $252,680.00 |
DisclosureSEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,950,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 15, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $1.22 | $183,210.00 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,750,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2179 to $1.2232. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 14, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 133,220 | $1.21 | $161,542.57 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,600,000 F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 13, 2025 Filed Aug 16, 2025 01:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 75,000 | $1.31 | $98,280.00 |
DisclosureSEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,466,780 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.3075 to $1.3118. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 58,215 | $1.07 | $61,998.98 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,806,470 F4 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. F5 · price: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member. F6 · balance_after: Includes RSUs. F7 · ownership.direct: The securities are owned directly by Eli Casdin. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $1.07 | $580,425.00 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F3 · ownership.nature: The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $1.07 | $580,425.00 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,391,780 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:19 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 4,820,959 | $1.07 | $5,134,321.34 |
DisclosureSEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 58,846,780 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 27, 2024 Filed Aug 30, 2024 00:30 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $2.19 | $546,750.00 |
DisclosureSEC source: 0000919574-24-005134 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 54,025,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1746 to $2.1953. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 00:10 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $2.15 | $322,455.00 |
DisclosureSEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotet Disclosed balance after: 53,775,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1223 to $2.1719. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 00:10 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 292,100 | $2.13 | $620,975.39 |
DisclosureSEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,625,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.115 to $2.1505. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 22, 2024 Filed Aug 27, 2024 00:10 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 307,900 | $1.96 | $602,806.62 |
DisclosureSEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,333,721 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.9464 to $1.9587. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 00:47 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $1.90 | $951,950.00 |
DisclosureSEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,025,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8927 to $1.9364. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 00:47 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $1.87 | $936,700.00 |
DisclosureSEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,525,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8596 to $1.8828. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 19, 2024 Filed Aug 22, 2024 00:47 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $1.85 | $463,225.00 |
DisclosureSEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,025,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8279 to $1.8749. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 23:52 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 1,200,000 | $1.59 | $1,913,520.00 |
DisclosureSEC source: 0000919574-24-004802 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 51,775,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $6.58 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024 and August 13, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5516 to $1.605. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 00:15 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 550,000 | $1.62 | $890,560.00 |
DisclosureSEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,575,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.6151 to $1.6303. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 00:15 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $1.64 | $820,600.00 |
DisclosureSEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,025,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.6331 to $1.6978. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 09, 2024 Filed Aug 14, 2024 00:15 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 525,408 | $1.61 | $848,481.38 |
DisclosureSEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 49,525,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.611 to $1.62. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 08, 2024 Filed Aug 10, 2024 01:34 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 569,562 | $1.64 | $932,600.82 |
DisclosureSEC source: 0000919574-24-004339 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 49,000,413 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.565 to $1.68. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 07, 2024 Filed Aug 10, 2024 01:34 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $1.57 | $786,200.00 |
DisclosureSEC source: 0000919574-24-004339 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 48,430,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.525 to $1.595. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 01:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 200,000 | $1.58 | $316,780.00 |
DisclosureSEC source: 0000919574-24-004280 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 47,930,821 F4 · kind: The purchase of Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 200,000 Shares, with the sale of 200,000 shares of Issuer common stock at a price of $2.05 per share by an entity in which the Disgorging Parties had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agreed to pay to Issuer, upon settlement of the purchase, $83.91 which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5664 to $1.5997. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 02, 2024 Filed Aug 7, 2024 01:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 1,000,000 | $1.63 | $1,631,900.00 |
DisclosureSEC source: 0000919574-24-004280 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 47,730,821 F1 · kind: The purchase of Issuer's Common Stock ("Shares") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,000,000 Shares, with the sale of 1,000,000 shares of Issuer common stock at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the date reported on the Form 4 filed on June 21, 2024 by the Disgorging Parties. The Disgorging Parties agreed to pay to Issuer, upon settlement of the purchase, $376.24 which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity which made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5462 to $1.6583. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 1,200,000 | $2.05 | $2,460,000.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 0 F5 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify. F6 · ownership.nature: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 545,000 | $2.05 | $1,117,250.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 545,000 F3 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify"). F4 · ownership.nature: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 655,000 | $2.05 | $1,342,750.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 46,730,821 F1 · kind: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2 · ownership.nature: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 100,000 | $2.60 | $260,000.00 |
DisclosureSEC source: 0000919574-24-003356 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,075,821 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 22, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 150,000 | $2.58 | $387,735.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,975,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5771 to $2.5865. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 350,000 | $2.56 | $895,930.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,825,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5597 to $2.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 20, 2024 Filed May 22, 2024 23:53 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 100,000 | $2.58 | $258,130.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,475,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5791 to $2.5858. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.